Profile data is unavailable for this security.
About the company
JW Cayman Therapeutics Co Ltd is a China-based company mainly engaged in the clinical and pre-clinical stage cell therapy. The Company is focuses on developing cell therapies for the China market to transform the treatment of cancer for Chinese patients. Through its subsidiary, it has built an integrated platform focused on developing, manufacturing and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its main product candidate, relmacabtagene autoleucel (relma-cel), is an autologous anti-CD19 CAR-T therapy for relapsed or refractory (r/r) B-cell lymphoma. The Company mainly conducts its businesses in the China market.
- Revenue in HKD (TTM)187.93m
- Net income in HKD-830.17m
- Incorporated2017
- Employees398.00
- LocationJW (Cayman) Therapeutics Co LtdNo 225 Meisheng RoadPilot Free Trade Zone, 4f, Building 42SHANGHAI KY1-1104ChinaCHN
- Websitehttps://www.jwtherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genor Biopharma Holdings Ltd | 0.00 | -728.96m | 666.47m | 104.00 | -- | 0.5096 | -- | -- | -1.44 | -1.44 | 0.00 | 2.55 | 0.00 | 0.00 | -- | 0.00 | -37.91 | -55.46 | -44.02 | -63.73 | -- | 66.56 | -- | -14,819.18 | 5.38 | -- | 0.006 | -- | -100.00 | -- | 7.65 | -- | -48.85 | -- |
| Lee's Pharmaceutical Holdings Ltd | 1.05bn | 16.70m | 730.16m | 1.06k | 43.72 | 0.3581 | 4.68 | 0.6934 | 0.0284 | 0.0284 | 1.79 | 3.46 | 0.3713 | 1.83 | 10.75 | 996,247.90 | 0.7033 | 13.33 | 0.88 | 17.76 | 52.35 | 61.92 | 1.89 | 36.20 | 0.5526 | 3.90 | 0.0943 | 3.59 | -14.61 | -1.53 | -67.44 | -47.49 | -12.19 | -31.34 |
| Jbm (Healthcare) Ltd | 610.30m | 97.99m | 775.44m | 258.00 | 8.56 | 0.8269 | 5.21 | 1.27 | 0.1087 | 0.1087 | 0.6786 | 1.12 | 0.4406 | 5.88 | 4.10 | 2,000,994.00 | 7.56 | 3.33 | 9.04 | 4.93 | 47.70 | 45.97 | 17.17 | 10.97 | 1.45 | 22.15 | 0.1211 | 13.81 | 28.11 | 14.51 | 131.90 | 6.14 | -5.09 | -- |
| Transcenta Holding Limited | 58.21m | -500.02m | 776.75m | 215.00 | -- | 0.6974 | -- | 13.34 | -1.23 | -1.23 | 0.143 | 2.55 | 0.0281 | 2.05 | 1.49 | 270,738.20 | -24.17 | -- | -33.97 | -- | 26.74 | -- | -859.01 | -- | 1.20 | -32.87 | 0.285 | -- | -47.15 | -- | -13.72 | -- | -- | -- |
| Pak Fah Yeow International Ltd | 259.16m | 105.04m | 788.45m | 102.00 | 7.51 | 1.03 | 7.01 | 3.04 | 0.337 | 0.337 | 0.8316 | 2.46 | 0.2995 | 2.88 | 22.18 | 2,540,765.00 | 12.14 | 3.99 | 12.60 | 4.18 | 84.45 | 80.79 | 40.53 | 21.27 | 6.90 | 10.08 | 0.0062 | 100.68 | 76.06 | 12.94 | 250.66 | 23.02 | 18.83 | -8.06 |
| Zhaoke Ophthalmology Ltd | 20.27m | -416.21m | 819.21m | 313.00 | -- | 0.37 | -- | 40.42 | -0.7652 | -0.7652 | 0.0373 | 4.05 | 0.0075 | -- | 0.531 | 64,754.11 | -15.43 | -- | -17.27 | -- | 75.98 | -- | -2,053.54 | -- | 5.32 | -47.54 | 0.1041 | -- | -- | -- | 5.47 | -- | -- | -- |
| Jilin Provnc Hnn Chnglng Bio-pharm CoLtd | 909.68m | 160.21m | 851.58m | 848.00 | 5.32 | 0.5322 | 6.94 | 0.9361 | 0.286 | 0.286 | 1.62 | 2.86 | 0.3587 | 2.18 | 2.94 | 1,072,734.00 | 6.32 | 7.67 | 9.12 | 10.48 | 69.40 | 78.79 | 17.61 | 20.68 | 1.51 | -- | 0.0515 | 7.22 | -0.0049 | 5.38 | -23.43 | -1.67 | -1.14 | -- |
| Brii Biosciences Ltd | 666.95k | -188.98m | 853.88m | 128.00 | -- | 0.2531 | -- | 1,280.27 | -0.2598 | -0.2598 | 0.0009 | 4.62 | 0.0002 | -- | -- | 5,210.57 | -5.60 | -- | -5.84 | -- | -- | -- | -29,881.69 | -- | -- | -- | 0.001 | -- | -98.80 | -- | 63.90 | -- | -- | -- |
| Zhongzhi Pharmaceutical Holdings Ltd | 2.22bn | 175.95m | 863.60m | 2.64k | 4.81 | 0.762 | 2.99 | 0.3898 | 0.2077 | 0.2077 | 2.62 | 1.31 | 1.12 | 2.53 | 10.54 | 838,353.60 | 8.95 | 7.69 | 14.15 | 11.75 | 59.73 | 60.44 | 8.01 | 6.73 | 0.894 | -- | 0.1424 | 42.46 | 12.26 | 12.41 | 53.00 | 13.86 | 17.65 | 3.22 |
| Fusen Pharmaceutical Co Ltd | 611.40m | -39.21m | 892.45m | 1.15k | -- | 1.47 | -- | 1.46 | -0.0525 | -0.0525 | 0.813 | 0.8122 | 0.4199 | 1.95 | 8.36 | 532,579.00 | -2.69 | 0.9678 | -5.54 | 1.74 | 52.95 | 51.95 | -6.42 | 2.59 | 0.6096 | 0.756 | 0.3797 | 27.95 | 15.02 | 4.13 | -4.83 | -- | 0.2124 | -- |
| JW (Cayman) Therapeutics Co Ltd | 187.93m | -830.17m | 965.95m | 398.00 | -- | 0.5279 | -- | 5.14 | -2.02 | -2.02 | 0.4567 | 4.41 | 0.0704 | 1.68 | 65.54 | 472,190.20 | -31.11 | -39.77 | -35.21 | -44.00 | 50.74 | -- | -441.74 | -1,316.81 | 3.86 | -47.82 | 0.1592 | -- | 19.32 | -- | 9.23 | -- | -19.87 | -- |
| Sunho Biologics Inc | -100.00bn | -100.00bn | 1.11bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -155.25 | -- | -- | -- |
| Hbm Holdings Ltd | 699.66m | 178.21m | 1.12bn | 177.00 | 6.02 | 1.14 | 5.24 | 1.60 | 0.2424 | 0.2424 | 0.9533 | 1.28 | 0.3886 | 3.90 | 3.01 | 3,952,904.00 | 9.88 | -54.61 | 14.13 | -66.04 | 97.73 | 97.81 | 25.43 | -400.28 | 3.28 | 6.98 | 0.3556 | -- | 120.13 | 127.06 | 116.61 | -- | -12.62 | -- |
| Jacobson Pharma Corporation Ltd | 1.68bn | 212.16m | 1.18bn | 1.59k | 5.30 | 0.4947 | 2.98 | 0.7012 | 0.1112 | 0.1409 | 0.8822 | 1.19 | 0.3722 | 2.87 | 7.50 | 940,829.50 | 5.16 | 4.91 | 6.61 | 6.60 | 42.05 | 41.81 | 13.85 | 14.32 | 1.01 | 5.62 | 0.3646 | 35.97 | 11.91 | 2.89 | 41.30 | 4.42 | -6.22 | 6.39 |
| Ascletis Pharma Inc | 61.18m | -156.43m | 1.23bn | 219.00 | -- | 0.4984 | -- | 20.03 | -0.147 | -0.147 | 0.057 | 2.43 | 0.022 | 2.30 | 3.86 | 279,352.10 | -5.62 | -6.43 | -5.91 | -6.64 | 45.92 | 35.67 | -255.70 | -243.38 | 16.54 | -6.09 | 0.0036 | -- | 4.63 | -19.39 | 54.04 | -- | -20.44 | -- |
| Jacobio Pharmaceuticals Group Co Ltd | 68.66m | -388.19m | 1.24bn | 301.00 | -- | 1.06 | -- | 17.99 | -0.5022 | -0.5022 | 0.0888 | 1.47 | 0.0419 | -- | 5.21 | 228,115.30 | -23.66 | -45.76 | -26.86 | -49.30 | 5.04 | -- | -565.36 | -372.22 | -- | -- | 0.1636 | -- | -33.66 | -- | 3.43 | -- | 19.18 | -- |
Data as of May 31 2024. Currency figures normalised to JW (Cayman) Therapeutics Co Ltd's reporting currency: Hong Kong Dollar HKD
2.01%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| JPMorgan Asset Management (UK) Ltd.as of 31 Dec 2022 | 2.72m | 0.66% |
| Bosera Asset Management Co., Ltd.as of 31 Dec 2022 | 2.56m | 0.62% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 917.99k | 0.22% |
| Dimensional Fund Advisors LPas of 09 May 2024 | 840.50k | 0.20% |
| Fullgoal Fund Management Co., Ltd.as of 31 Dec 2023 | 300.00k | 0.07% |
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 277.00k | 0.07% |
| China Asset Management (Hong Kong) Ltd.as of 31 Dec 2023 | 262.50k | 0.06% |
| ICBC Credit Suisse Asset Management Co., Ltd.as of 31 Dec 2023 | 200.00k | 0.05% |
| PMG Investment Solutions AGas of 09 Sep 2022 | 129.00k | 0.03% |
| SSgA Funds Management, Inc.as of 09 May 2024 | 108.85k | 0.03% |
More ▼
Data from 31 Dec 2023 - 22 May 2024Source: FactSet Research Systems Inc.
